In preclinical studies, siltuximab inhibited IL-6–induced activation of ovarian cancer cells [49], inhibited IL-6–induced survival of advanced prostate cancer [57], suppressed lung cancer growth in mouse xenograft models [55], and enhanced melphalan cytotoxicity in a preclinical multiple myeloma model [51]. This evidence concerns the gene IL6 and lung cancer.